Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE38115 | AVANIR PHARMS | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
Jan, 2016
(8 years ago) | |
US8227484 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Jul, 2023
(9 months ago) | |
US7659282 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Aug, 2026
(2 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Oct 29, 2013 |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Dosage: CAPSULE;ORAL